Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 8, 2012, Pages 1177-1186

  Casapao, Anthony M ^a   Steed, Molly E ^b   Levine, Donald P ^c   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute bacterial skin and skin structure infection; Ceftaroline; Ceftaroline fosamil; Cephalosporin; Community acquired bacterial pneumonia; Methicillin resistant Staphylococcus aureus; Penicillin resistant Streptococcus pneumoniae; PPI 0903; PPI 0903M; Skin and soft tissue; Staphylococcus aureus; Streptococcus pneumoniae; T 91825; TAK 599

Indexed keywords

AZTREONAM; CEFOTAXIME; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CLARITHROMYCIN; CYTOCHROME P450; PENICILLIN BINDING PROTEIN 2A; PENICILLIN BINDING PROTEIN 2X; VANCOMYCIN;

ACINETOBACTER; ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CROSS REACTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG WITHDRAWAL; HAEMOPHILUS INFLUENZAE; HUMAN; KIDNEY FUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY (TOPIC); PEPTOSTREPTOCOCCUS; PHASE 3 CLINICAL TRIAL (TOPIC); PROPIONIBACTERIUM; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL;

EID: 84861314610     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.685718     Document Type: Review

References (58)

1. Gertz RE Jr, Li Z, Pimenta FC, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010;201 (5): 770-5
2. Lessa FC, Mu Y, Davies J, et al.comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006 - 2007. Clin Infect Dis 2010;51 (8): 925-8
3. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352 (14): 1436-44
4. Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012;50 (2): 238-45
5. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298 (15): 1763-71 (Pubitemid 47598444)
6. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42 (Suppl 1): S3-4 (Pubitemid 41832059)
7. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40 (1): 135-6 (Pubitemid 27341646)
8. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51 (26): 565-7
9. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997 - 2001. Clin Infect Dis 2003;36 (4): 429-39 (Pubitemid 36241308)
10. Product information. Telfaro (Ceftaroline Fosamil). Forest Laboratories, Inc.; St. Louis, MO: 2011
11. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 2010;30 (4): 375-89
12. Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2011;55 (7): 3522-6
13. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010;54 (5): 1670-7
14. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline (CPT) to penicillin-binding proteins (PBPs) of Streptococcus pneumoniae (SPN) and methicillin-resistant Staphylococcu aureus (MRSA). Poster presented at 48th Annual International Conference on Antimicrobial Agents and Chemotherapy/ 46th Infectious Diseases Society of America Annual Meeting; 25 - 28 October 2008
15. Ikeda Y, Ban J, Ishikawa T, et al. Stability and stabilization studies of TAK-599 (Ceftaroline Fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825. Chem Pharm Bull 2008;56 (10): 1406-11
16. Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11 (11): 2427-37 (Pubitemid 36539379)
17. Villegas-Estrada A, Lee M, Hesek D, et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc 2008;130 (29): 9212-13 (Pubitemid 352031115)
18. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010;65 (4): 713-16
19. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010;65 (Suppl 4): iv17-31
20. Karlowsky JA, Adam HJ, Decorby MR, et al. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob Agents Chemother 2011;55 (6): 2837-4
21. Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother 2011;55 (9): 4154-60
22. Sader HS, Farrell DJ, Jones RN. In vitro activity of ceftaroline tested against bacterial pathogens frequently isolated in United States (USA) medical centers: results from the AWARE surveillance program. Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 16 - 20 September 2011
23. Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010;54 (6): 2716-19
24. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52 (3): 1153-5 (Pubitemid 351358404)
25. Saravolatz LD, Pawlak J, Johnson L. In vitro activity of ceftaroline agains CA-MRSA, VISA, VRSA, and daptomycin-nonsusceptible Staphylococcus aureus (DNSSA). Presented as poster at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy 46th Infectious Diseases Society of America; 25 - 28 October 2008; Washington, DC
26. Jacqueline C, Amador G, Batard E, et al.comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2011;66 (4): 863-6
27. Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2011;55 (7): 3522-6
28. Critchley IA, Eckburg PB, Jandourek A, et al. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011;66 (Suppl 3): iii45-51
29. Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008;52 (11): 4209-10
30. Ge Y, Biek D, Talbot GH, et al. In vitro profiling of ceftaroline against acollection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52 (9): 3398-407
31. Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, anovel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004;10 (3): 146-56 (Pubitemid 39044967)
32. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int JAntimicrob Agents 2009;33 (6): 515-19
33. Croisier-Bertin D, Piroth L, Charles PE,et al. Ceftaroline versus ceftriaxone in ahighly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother 2011;55 (7): 3557-63
34. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49 (8): 3501-12 (Pubitemid 41060605)
35. Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60 (2): 300-11 (Pubitemid 47243878)
36. Citron DM, Tyrrell KL, Merriam CV, et al. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010;54 (4): 1627-32
37. Snydman DR, Jacobus NV, McDermott LA. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates. Antimicrobial Agents and Chemotherapy 2011;55 (1): 421-5
38. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK- 599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50 (4): 1376-83
39. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 h against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011;55 (9): 4028-32
40. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against gram-positive organisms. Antimicrob Agents Chemother 2009;53 (10): 4537-9
41. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009;53 (3): 1271-4
42. Jones RN, Fritsche TR, Ge Y, et al. Evaluation of PPI-0903M (T91825), anovel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56 (6): 1047-52 (Pubitemid 43009818)
43. Clark C, McGhee P, Appelbaum PC, et al. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob Agents Chemother 2011;55 (5): 2344-51
44. Mushtaq S, Livermore DM. AmpC induction by ceftaroline. J Antimicrob Chemother 2010;65 (3): 586-8
45. Ge JY, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M). Poster presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27 - 30 September 2006; San Francisco, CA
46. Riccobene T, Fang E, Thye DA. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of caftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. Presented as poster at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy 46th Infectious Diseases Society of America; 25 - 28 October 2008; Washington, DC
47. Ge JY, Liao S, Talbot GH. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infections (cSSSI). Presented as poster at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 - 20 September 2007; Chicago, IL
48. Ge JY, Liao S, Thye DA, et al. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI). Presented as poster at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 - 20 September 2007; Chicago, IL
49. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65 (Suppl 4): iv41-51
50. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65 (Suppl 4): iv53-65
51. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66 (Suppl 3): iii19-32
52. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66 (Suppl 3): iii33-44
53. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336 (4): 243-50 (Pubitemid 27044625)
54. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase III trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010;51 (12): 1395-405
55. Talbot GH, Thye D, Das A, et al. Phase II study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51 (10): 3612-16 (Pubitemid 47519351)
56. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase III, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51 (6): 641-50
57. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010;54 (7): 3027-30
58. Riccobene T, Jakate A, Rank D, et al. An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis. Poster presented at European congress of clinical microbiology and infectious diseases; 16 - 19 May 2009; Helsinki, Finland